Search clinical trials for: Combination BNT162b2 and BNT162b2 OMI

Total 5552 results

BioNTech SE

Active, not recruiting

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults

RNA Virus Infections | Virus Diseases | Vaccine Adverse Reaction | Infection Viral | Infections, Respiratory | Protection Against COVID-19 and Infections With SARS CoV 2

Germany
BioNTech SE
Pfizer

Completed

A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals

COVID-19 | SARS-CoV-2 Infection

United States
BioNTech SE
Pfizer

Completed

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

COVID-19 | SARS-CoV-2 Infection

United States, Germany, Turkey, South Africa, Argentina, Brazil
BioNTech SE
Pfizer

Completed

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

COVID-19 | SARS-CoV-2 Infection

United States, Brazil, South Africa, Germany, Canada, Israel
BioNTech SE
Pfizer

Active, not recruiting

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

COVID-19 | SARS-CoV-2 Infection

United States
Pfizer

Completed

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

Healthy Participants

United States
Pfizer

Active, not recruiting

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

COVID-19 | Influenza, Human | SARS-CoV-2 Infection

United States
BioNTech SE
Pfizer

Active, not recruiting

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

COVID-19 | SARS-CoV-2 Infection

United States
Murdoch Childrens Research Institute
Coalition for Epidemic Preparedness Innovations; The Peter Doherty Institute...

Withdrawn

COVID-19 Fourth Dose Study in Australia

COVID-19

Australia
BioNTech SE

Completed

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

COVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)

United States, Germany, Turkey, South Africa
BioNTech SE
Pfizer

Completed

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

COVID-19 | SARS-CoV-2 Infection

United States
BioNTech SE
Pfizer

Completed

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

SARS-CoV-2 Infection, COVID-19

United States, Spain, Finland, Poland, Mexico, Brazil
Universiteit Antwerpen

Completed

Immunogenicity After COVID-19 Vaccines in Adapted Schedules (IMCOVAS)

COVID-19 | Coronavirus Disease 2019

Belgium
BioNTech SE
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

COVID-19 | Influenza, Human

United States
Pfizer

Completed

A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People

COVID-19

Indonesia
The University of Hong Kong

Recruiting

Intradermal COVID-19 Vaccination in the Immunocompromised

Immunocompromised Patients | Intradermal Covid-19 Vaccine | Immungenicity and Safety | Randomized Trial

Hong Kong
BioNTech SE
Pfizer

Completed

Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years

SARS-CoV-2 Infection, COVID19

United States, Brazil, Germany, Mexico
BioNTech SE
Pfizer

Completed

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

COVID-19 | SARS-CoV-2 Infection

United States
Shaare Zedek Medical Center

Completed

Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers

COVID-19 | Myocardial Injury | Vaccine Adverse Reaction

Israel
Pontificia Universidad Catolica de Chile

Recruiting

Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment

Sars-CoV-2 Infection

Chile
Albert B. Sabin Vaccine Institute
Stanford University; Aga Khan University; Oswaldo Cruz Foundation

Completed

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

COVID-19

Brazil, Pakistan
BioNTech SE
Pfizer

Recruiting

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

COVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2 | SARS-CoV-2 Virus

United States, South Africa, Brazil, Puerto Rico
Montefiore Medical Center
Albert Einstein College of Medicine

Recruiting

Booster Dose Trial

Cancer

United States
The University of Hong Kong

Active, not recruiting

Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)

COVID 19 Vaccine

Hong Kong
Pfizer

Completed

Drug Use Investigation of COMIRNATY Intramuscular Injection

COVID-19

Japan
Sheba Medical Center

Active, not recruiting

Fourth BNT162b2 COVID-19 Vaccine Dose

COVID-19 Pandemic

Israel
BioNTech SE
Pfizer

Completed

To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

COVID-19 | SARS-CoV-2 Infection | Maternal Immunization

United States, United Kingdom, Spain, Brazil, South Africa
BioNTech SE
Pfizer

Completed

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

COVID-19 | SARS-CoV-2 Infection

Japan
Pfizer

Completed

Special Investigation of COMIRNATY in the Population With Underlying Diseases

COVID-19

Japan
BioNTech SE
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Completed

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population

SARS-CoV-2

China
BioNTech SE
Pfizer

Withdrawn

A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children

COVID-19
Humanity & Health Medical Group Limited

Completed

Antibody Response to COVID-19 Vaccines in Liver Disease Patients

Chronic Liver Disease

Hong Kong
National Institute of Allergy and Infectious Diseases...

Completed

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

COVID-19

United States
Soroka University Medical Center
Ben-Gurion University of the Negev

Active, not recruiting

Prospective Monitoring of BNT162b2 Second Vaccination Booster Effects in Health Care Workers (HCW)

Coronavirus Infections

Israel
BioNTech SE

Completed

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects

COVID-19 | SARS-CoV-2 Infection

Germany
The University of Hong Kong

Active, not recruiting

Covid-19 Vaccination in Adolescents and Children (COVAC)

Covid19

China
KK Women's and Children's Hospital
Duke-NUS Graduate Medical School

Recruiting

Determining Reactogenicity and Immunogenicity of Delayed COVID-19 Vaccine Schedule in Children

COVID-19 | Vaccine Reaction | Children, Only

Singapore
DHR Health Institute for Research and Development

Recruiting

PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS

COVID-19 | SARS CoV 2 Infection

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings (PACIFIC)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia

France
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France

Completed

BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers (CoviCompareP)

Healthy | Immunization; Infection

France
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Evaluation of the Impact of the Anti COVID-19 Vaccination Campaign Addressed to the Employees of an Italian Hospital.

COVID-19

Italy
University of Debrecen

Completed

Serology After BBIBP-CorV Inactivated Vaccine Combined With BNT62b2 mRNA Booster Vaccine

Basic BBIBP-CorV Vaccination is Not as Effective as BNT162b

Hungary
Federal University of Espirito Santo
Butantan Institute; Centro de Pesquisas René Rachou; Secretaria de Estado da...

Recruiting

Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents (Curumim)

COVID-19

Brazil
Korea University Guro Hospital
Ajou University School of Medicine; Korean Center for Disease Control and Prevention and other collaborators

Recruiting

Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms

Inflammation | Vaccine Adverse Reaction | Vaccine Immune Response | COVID-19 Vaccination

Korea, Republic of
Ente Ospedaliero Ospedali Galliera
University of Genoa

Recruiting

BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment (UNICO)

Neoplasms | Cancer, Treatment-Related

Italy
University of Roma La Sapienza
ICOT University Hospital

Recruiting

Antibodies Response to mRNA Vaccine Against Covid-19 (SCAREAID)

Covid-19

Italy
Medical University of Vienna

Active, not recruiting

Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients (BOOST_TX)

COVID-19

Austria
BioNTech SE
Pfizer

Completed

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

COVID-19 | SARS-CoV-2 Infection

Australia, New Zealand
Butantan Institute

Active, not recruiting

Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine (Butanvac)

Coronavirus Infections | Healthy

Brazil
Pfizer

Completed

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

COVID-19 | SARS-CoV-2 Infection

Australia, New Zealand

Search clinical trials for: Combination BNT162b2 and BNT162b2 OMI

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations